

Sex differences in the cardiovascular effects of GnRH analogues

Matthew W.S. Lim¹, Angela K. Lucas-Herald^{1,2}, Avril Mason², Christian Delles¹, and Paul J. Connelly¹

¹University of Glasgow BHF Glasgow Cardiovascular Research Centre, School of Cardiovascular & Metabolic Health, University of Glasgow, Glasgow, UK

²Department of Paediatric Endocrinology, Royal Hospital for Children, Glasgow, UK

Correspondence to

Matthew W.S. Lim, e-mail: 2362717L@student.gla.ac.uk

Paul J. Connelly, e-mail: Paul.Connelly@glasgow.ac.uk

University of Glasgow BHF Glasgow Cardiovascular Research Centre, School of Cardiovascular & Metabolic Health, University of Glasgow, 126 University Place, Glasgow G12 8TA, UK

Short title: GnRH analogues and cardiovascular disease

Keywords: cardiovascular, gonadotropin releasing hormone, testosterone, oestrogen

Word Count: 4707

Abstract

The integral role of the hypothalamic-pituitary-gonadal axis in reproductive processes makes it a prime therapeutic target. By inhibiting sex steroid synthesis, gonadotropin releasing hormone (GnRH) analogues are used in the management of cancers, benign neoplasms, infertility and gender dysphoria. However, the wide application of these therapeutics raises concerns regarding the unintended effects upon the cardiovascular system. In males with prostate cancer, GnRH analogues when used as an androgen deprivation therapy appear to increase the risk of cardiovascular disease, which is the leading cause of death in this population. Therefore, due to the utilisation of GnRH analogues across the lifespan and gender spectrum, this relationship merits discussion. Existing data suggest an association between GnRH analogues and major adverse cardiovascular events in males. Conversely, females receiving GnRH analogues for breast cancer treatment appear to be at an increased risk of developing hypertension. In this narrative review, we describe the uses of GnRH analogues in adults, adolescents and children. We discuss whether sex plays a role in the cardiovascular effects of GnRH analogues and explore the significance of sex hormone receptors in the vasculature. We also consider confounding factors such as malignancy, advanced age and infertility.

Introduction

The gonadotropins, luteinising hormone (LH) and follicle stimulating hormone (FSH), are integral to male and female reproductive processes, including the menstrual cycle, gamete maturation and pubertal development via the secretion of gonadal sex steroids (oestrogen and testosterone) (Flanagan and Manilall 2017). This is achieved and regulated via the activation of the anterior pituitary gonadotropin releasing hormone (GnRH) receptors via its decapeptide ligand. Consequently, the GnRH receptor has been identified as a prime therapeutic target in the management of sex steroid sensitive-malignancies, benign neoplasms, infertility and for the cessation of puberty (Fig. 1).

GnRH analogues consist of agonists and antagonists (Fig. 2). GnRH secretion is pulsatile, and therefore initial GnRH receptor stimulation via agonists promotes the secretion of gonadotropins and sex steroids. Chronic activation results in the downregulation of these receptors, subsequently reducing the synthesis of gonadotropins. Conversely, GnRH antagonists directly inhibit the activity of GnRH receptors in the anterior pituitary gland (Shore 2013). GnRH agonists achieve gonadotropin and sex steroid suppression within approximately 1 month, while GnRH antagonists facilitate almost immediate suppression (Klotz, et al. 2008; Shore 2013; Williams, et al. 1986).

Beyond direct effects on reproductive physiology, GnRH suppression may disrupt multiple organ systems following the loss of sex steroid regulation and function. The detrimental influence of gonadal suppression in some aspects of health are well established, such as the relationship between GnRH analogues with bone health and fracture risk (Shahinian, et al. 2005). However, the effects of these drugs on the cardiovascular system are less well understood. This relationship merits discussion given the diverse utilisation of GnRH analogues across the lifespan and gender spectrum, and high prevalence of cardiovascular mortality among patients receiving GnRH analogues (Sturgeon, et al. 2019).

In this narrative review, we describe the use of GnRH analogues in adults, adolescents and children. We establish whether sex plays a role in the cardiovascular effects of GnRH analogues and explore the significance of sex hormone receptors in the vasculature.

Cardiovascular outcomes in males

Prostate cancer

GnRH analogues (e.g. abarelix, degarelix, leuprorelin, goserelin) form an integral component of androgen deprivation therapy (ADT) used in the management of localised and metastatic prostate cancer (Cornford, et al. 2021; Mottet, et al. 2021), as alternatives to oestrogen and orchidectomy (Levine, et al. 2010). Testosterone depletion ameliorates androgen receptor activation, thereby preventing the proliferation of prostate cancer cells (Packer and Maitland 2016). GnRH analogues may be combined with direct antiandrogens, such as bicalutamide or abiraterone, which directly inhibit the androgen receptor or androgen synthesis.

Over the past decade we have seen a growing interest in the cardiovascular effects of GnRH agonists. Since 2010, the U.S. Food and Drug Administration has issued warnings regarding the increased risk of myocardial infarction, sudden cardiac death and stroke in this drug class. The decision followed emerging studies demonstrating a link between the use of GnRH agonist and cardiovascular disease in males with prostate cancer (Supplementary Table 1) (Keating, et al. 2006; Keating, et al. 2010; Van Hemelrijck, et al. 2010).

The first of the studies was the Surveillance, Epidemiology and End Results Medicare study published in 2006 (Keating et al. 2006). In this population-based analysis of 73,169 males diagnosed with locoregional prostate cancer from 1992 to 1999, males receiving GnRH agonists were at increased risk of ischaemic heart disease (hazard ratio [HR] 1.16, 95% confidence interval [CI] 1.10, 1.21), myocardial infarction (HR 1.11, 95% CI

1.01, 1.21) and sudden cardiac death (HR 1.16, 95% CI 1.05, 1.27) compared to those not receiving any form of ADT.

Two subsequent observational studies have shown similar results (Keating *et al.* 2010; Van Hemelrijck *et al.* 2010). Data obtained from the Veterans' Healthcare Administration (Keating *et al.* 2010) demonstrated substantial increases in ischaemic heart disease (HR 1.19, 95% CI 1.10, 1.28), myocardial infarction (HR 1.28, 95% CI 1.08, 1.52), sudden cardiac death (HR 1.35, 95% CI 1.18, 1.54) and stroke (HR 1.22, 95% CI 1.19, 1.36). In addition, a study of the Swedish National Prostate Cancer Register (Van Hemelrijck *et al.* 2010) established an increased risk of cardiac arrhythmia (HR 1.27, 95% CI 1.10, 1.47) and heart failure (HR 1.46, 95% CI 1.28, 1.67) in GnRH agonist users when compared to the general population.

More recently, a Scottish observational study of 20,216 males diagnosed with prostate cancer from January 2009 to December 2015 found significant increases in overall cardiovascular events in those prescribed either GnRH agonists (adjusted HR 1.3, 95% CI 1.2, 1.4) or the GnRH antagonist degarelix (adjusted HR 1.5, 95% CI 1.2, 1.9), which followed a dose-response relationship (Cardwell, *et al.* 2020). Importantly, this increase in cardiovascular events was not observed in those utilising bicalutamide monotherapy, which suggests that relative rather than absolute reduction of testosterone concentrations in this cohort may confer a degree of cardio-protection.

Several recent meta-analyses have assessed this relationship. Liang *et al.* (Liang, *et al.* 2020) demonstrated that ADT, achieved via anti-androgens, orchiectomy, GnRH agonists, or combined therapy, substantially increased the risk of acute myocardial infarction (relative risk [RR] 1.19, 95% CI 1.02, 1.39). This association was particularly pronounced in those prescribed GnRH agonists, where an increased risk in acute myocardial infarction (RR 1.73, 95% CI 1.05, 2.85) and ischaemic heart disease (RR 2.09, 95% CI 1.02, 4.30) was observed. In a meta-analysis of ten observational studies by Liu *et al.* (Liu, *et al.* 2020), an increased risk of stroke was observed with any form of ADT (HR 1.13, 95% CI 1.02, 1.3),

which was evident in GnRH agonist users (HR 1.2, 95% CI 1.1, 1.3). Lastly, Zhao *et al.* (Zhao, et al. 2014) demonstrated an increase in cardiovascular mortality (RR 1.36, 95% CI 1.10, 1.68) in GnRH agonist users.

GnRH agonists do not appear to affect blood pressure in males. In a study by Smith *et al.* (Smith, et al. 2008), 12-month treatment with leuprorelin did not result in significant blood pressure changes among 26 males with prostate cancer (systolic blood pressure [SBP] -4 mmHg, diastolic blood pressure [DBP] -1 mmHg). In this study, androgen antagonist bicalutamide was used to counteract the initial surge in testosterone, however without a control group. Similarly, blood pressure changes did not differ between 16 males treated with goserelin and 15 untreated controls in another study (Dockery, et al. 2003).

Comparing agonists and antagonists

GnRH antagonists have been developed to circumvent the initial surge in testosterone associated with GnRH agonists (Persson, et al. 2009). In animal models, GnRH antagonists have demonstrated a favourable safety profile compared to other forms of ADT with respect to reduced atheroma formation and necrosis (Hopmans, et al. 2014; Knutsson, et al. 2016), and increased stability of established plaques (Knutsson et al. 2016).

Observational studies have thus far been inconclusive (Sciarra, et al. 2021). George *et al.* reported that users of GnRH antagonists compared with agonists were associated with a higher risk of acute myocardial infarction (HR 1.62, 95% CI 1.11, 2.35) and arrhythmia (HR 1.55, 95% CI 1.11, 2.15) (George, et al. 2021). Conversely, a Taiwanese observational study involving 666 GnRH antagonist users and 1332 propensity-matched agonist users found a lower risk of major adverse cardiovascular events (MACE) (HR 0.48, 95% CI 0.25, 0.90) and cardiovascular death (HR 0.21, 95% CI 0.06, 0.70) in the antagonist group (Chen, et al. 2021). Similarly, data from UK general practices showed a lower number of cardiac events

among males receiving a GnRH antagonist (RR 0.39, 95% CI 0.19, 0.80), largely driven by a decreased risk of arrhythmia (RR 0.28, 95% CI 0.09, 0.87) (Davey and Kirby 2021).

Neutral results have been observed in a study using French health insurance data which found no significant difference in events of myocardial infarction (HR 1.14, 95% CI 0.47, 2.80) and ischaemic stroke (HR 1.25, 95% CI 0.59, 2.66) between agonist and antagonist users (Scailteux, et al. 2017). A similar study in Germany demonstrated that GnRH agonist users when compared to antagonist users were at a greater risk of developing hypertension (16.40 vs 6.90%) but not cardiovascular disease as a whole (40.26 vs 45.45%) (Hupe, et al. 2018).

Similarly, clinical trials have not produced conclusive evidence favouring either drug (Sciarra et al. 2021). In the first clinical trial with a cardiovascular endpoint (PRONOUNCE), the GnRH antagonist degarelix did not reduce MACE among males with prostate cancer and high cardiovascular risk (HR 1.28, 95% CI 0.59, 2.79) compared to the GnRH agonist leuprorelin (Lopes, et al. 2021). This trial prematurely ended at 12 months due to recruitment failure, and experienced lower than anticipated cardiovascular events, and therefore was underpowered and could not conclude on cardiovascular risk.

Null results were also observed in an earlier clinical trial by Smith *et al.* (Smith, et al. 2010) comparing the same drugs (Table 1). Similarly, degarelix did not reduce MACE when compared to the GnRH agonist goserelin in a Chinese study (Sun, et al. 2020). In contrast, the highly selective GnRH antagonist relugolix significantly reduced cardiovascular events when compared to the GnRH agonist leuprorelin (HR 0.46, 95% CI 0.24, 0.88) (Shore, et al. 2020).

Pooled data from prostate cancer trials suggested a potential benefit of GnRH antagonists. In a meta-analysis of ten randomised trials, decreases in MACE (RR 0.57, 95% CI 0.39, 0.81) and cardiovascular deaths (RR 0.49, 95% CI 0.25, 0.96) were seen in males receiving GnRH antagonists compared to agonists (Cirne, et al. 2021). The difference in

results may reflect baseline cardiovascular risk and study designs. In some of the evidence, the antagonist users had a shorter follow up (Lopes et al. 2021). The tailoring of GnRH antagonist to males with high cardiovascular risk may have nullified the beneficial effects of the drug (George et al. 2021).

In summary, there is an increased risk of atherosclerotic cardiovascular disease in males receiving GnRH analogues. The comparative safety of GnRH antagonist over agonist remains uncertain due and may be drug rather than class dependent.

Cardiovascular outcomes in females

Breast cancer

Oestrogen receptors (ERs) are expressed in 60-70% of breast cancers and represent an important component of breast carcinogenesis (Huang, et al. 2015). In ER-positive breast cancers, oestrogen binding encourages tumour growth and proliferation (Burstein 2020). Consequently, endocrine therapies that disrupt oestrogen signalling are used to ameliorate disease progression. Depending on menopausal status this involves selective ER modulators (tamoxifen); aromatase inhibitors (anastrozole, exemestane and letrozole) that inhibit the conversion of androgens to oestrogen; or GnRH agonists that facilitate ovarian function suppression (OFS) (Bui, et al. 2020). A Cochrane review of 8 randomised controlled trials showed that GnRH agonists were associated with a ~20% increase in overall and breast cancer-free survival compared to females who did not receive OFS (Bui et al. 2020).

A combined analysis from two clinical trials involving females with breast cancer (SOFT and TEXT) demonstrated that the rates of hypertension were more prevalent in those receiving OFS in combination with tamoxifen (24.6%, 95% CI 21.9, 25.4) or exemestane (24.3%, 95% CI 22.6, 26.1) compared to those receiving tamoxifen alone (18.0%, 95% CI 15.7, 20.5) (Francis, et al. 2018). All females in TEXT and 91% in SOFT received the GnRH agonist triptorelin as their choice of OFS (Regan, et al. 2013). The remaining participants

received oophorectomy or ovarian irradiation. Importantly, the incidence of cardiovascular outcomes was low in this analysis, potentially because of the short study duration and lack of prespecified endpoints.

In the E5188 trial, the addition of GnRH agonist goserelin to chemotherapy significantly increased the risk of hypertension by 8.1% (Davidson, et al. 2005). Interestingly, the addition of tamoxifen to chemotherapy and goserelin did not increase the incidence of hypertension (18.8 vs 17.2%), suggesting that ovarian suppression via GnRH analogues alone is sufficient to promote increased blood pressure in females with breast cancer. The lack of data assessing the addition of tamoxifen to chemotherapy precludes any conclusion on whether the effects of GnRH analogues are due to oestrogen deprivation, GnRH modulation or both.

A recent retrospective analysis of 172,850 females with breast cancer demonstrated that those receiving GnRH agonists had a significantly lower risk of developing ischaemic heart disease even after adjustments for age, breast cancer treatment (lumpectomy and radiotherapy) and comorbidities (adjusted HR 0.5, 95% CI 0.39, 0.64) (Chou, et al. 2022). However, no randomised control trial has been undertaken to assess whether this relationship is causal and therefore significant gaps persist in our understanding of the influence of these therapies on long-term cardiovascular outcomes in this population.

In vitro fertilisation (IVF)

During IVF treatment, GnRH analogues are used to reduce gonadotropin synthesis (Li, et al. 2013). The disruption of the menstrual cycle prevents premature surges of LH, allowing for the uninterrupted development of the follicle and oocyte (Albano, et al. 1996). Exogenous gonadotropins are subsequently introduced when sufficient endogenous gonadotropin has been suppressed (Manau, et al. 2002). When compared to human chorionic gonadotropins (HCGs), the use of GnRH agonists to trigger oocyte maturation reduces the risk of ovarian

hyperstimulation syndrome, albeit at a lower live birth rate (Youssef, et al. 2014). Following ovulation, the addition of GnRH agonist to progesterone for luteal phase support may improve the chance of a successful implantation (Linden, et al. 2015).

A case-control study showed that assisted conception with IVF was associated with an increased risk of pre-eclampsia (adjusted odds ratio [OR] 5.3, 95% CI 1.74, 15.89) when compared to those with unassisted pregnancies (Calhoun, et al. 2011). The findings agree with a previous meta-analysis which showed an increase in pre-eclampsia in mothers following IVF therapy (OR 1.55, 95% CI 1.23, 1.95) (Jackson, et al. 2004). In addition to demonstrating an increased risk of pre-eclampsia, a cohort study also found an increased risk of gestational hypertension among mothers who received IVF (OR 1.6, 95% CI 1.0, 2.5) (Shevell, et al. 2005).

The long-term effects of IVF on the cardiovascular system have also been studied. A meta-analysis of 6 observational studies by Dayan *et al.* (Dayan, et al. 2017) showed no long-term increase in cardiac events (HR 0.91, 95% CI 0.67, 1.25) or stroke (HR 1.25, 95% CI 0.96, 1.63) among females who received fertility therapy. The effects on hypertension remain inconclusive due to significant heterogeneity among the studies included (Farland, et al. 2015; Udell, et al. 2013; Westerlund, et al. 2014). The inclusion of non-IVF-based therapies precludes any firm conclusions on the long-term cardiovascular safety of IVF.

Acute cardiovascular changes among females receiving GnRH antagonist are consistent with normal pregnancy. A recent study demonstrated significant reductions in SBP and DBP in 82 females receiving IVF treatment that consisted of recombinant FSH, the GnRH antagonist cetrorelix and recombinant HCG (SBP -3.0 mmHg, DBP -2.7 mmHg) (Akçay and Özdemir 2021).

Pre-eclampsia is a leading cause of perinatal mortality, and may be associated with future cardiovascular morbidity and mortality (Irgens, et al. 2001). These observations may be explained by maternal risk factors (older age and obesity) and pregnancy-associated

complications (multiple gestation) associated with IVF (Dayan et al. 2017). However, due to the small number of studies included and the significant between-study heterogeneity, these results must be interpreted with caution.

Endometriosis and uterine fibroids

Endometriosis is a major cause of chronic pelvic pain among adolescents and adults (Janssen, et al. 2013). Conversely, uterine fibroids primarily presents with heavy menstrual bleeding (Wegienka, et al. 2003). The oestrogen-dependent nature of endometrial tissue development (Bulun 2009) allows for the use of GnRH analogues to induce endometrial atrophy, providing pain (Brown, et al. 2010) and menstrual relief (Schlaff, et al. 2020). In females eligible for surgery, GnRH agonists are used to down-size uterine fibroids and reduce anaemia, improving postoperative outcomes (Lethaby, et al. 2017).

An uncontrolled study reported no changes in SBP, DBP and heart rate among 18 females treated with 6-months of the GnRH agonist leuprorelin for endometriosis (Ferreira, et al. 2010). In the Elaris trials, three cases of hypertension were reported among females receiving the GnRH antagonist elagolix for uterine fibroids (Schlaff et al. 2020). None were reported in the placebo group.

Cardiovascular outcomes in transgender adults

In transgender men, GnRH agonists may be prescribed for six months prior to the initiation of testosterone to suppress menses (Hembree, et al. 2017). Likewise, GnRH agonists in combination with oestrogen therapy are used to suppress testosterone synthesis in transgender women (Hembree et al. 2017). Current studies involving transgender adults have focused on the cardiovascular effects of gender-affirming hormone therapy (Banks, et al. 2021) but not of GnRH analogues.

Cardiovascular outcomes in adolescents and children

Puberty blockers

The Endocrine Society recommends the use of GnRH agonists in young transgender people demonstrating persistent gender dysphoria or incongruence following the onset of pubertal physical changes (Hembree et al. 2017). GnRH agonists lead to prepubertal levels of sex hormones (Delemarre-Van De Waal and Cohen-Kettenis 2006), preventing further development of unwanted sex characteristics (Claahsen - van der Grinten, et al. 2021).

GnRH agonists provide the young person time and space to explore their gender identity with the support of Mental Health professionals prior to initiating treatments associated with irreversible changes. Such treatments may include gender-affirming hormone therapy, which has been shown to improve psychosocial function (Chen, et al. 2023). Through stopping pubertal progression, GnRH agonists alleviates distress and anxiety associated with the appearance of secondary sex characteristics.

The effects of pubertal suppression on blood pressure have been summarised in Table 2. A study of 19 transfeminine adolescents treated with the GnRH agonist triptorelin demonstrated no changes in blood pressure (SBP +0 mmHg, DBP +0 mmHg) (Perl, et al. 2021). However, a larger study reported increases in DBP (+4 mmHg, 95% CI 1, 7) but not SBP following triptorelin use over a shorter period (Klaver, et al. 2020). Evidence for transmasculine adolescents are similarly equivocal. A study of 15 transmasculine adolescents receiving triptorelin treatment reported significant increases in DBP (+7 mmHg) (Perl, et al. 2020). However, two larger studies did not find any changes in blood pressure after triptorelin use in transmasculine adolescents (Klaver et al. 2020; Stoffers, et al. 2019).

Transgender adolescents may have different baseline blood pressures compared to their cisgender counterparts. In a cross-sectional study of 78 transgender adolescents prior to receiving puberty blockers or gender-affirming hormone therapy, the transgender cohort had increased SBP and DBP compared to their cisgender peers of the same natal sex

(Millington, et al. 2020). Although the authors have acknowledged that variations in blood pressure measurement between the two cohorts may explain the differences, the findings raise questions on the validity of comparing transgender individuals to members of the same natal sex (Connelly, et al. 2019).

None of the blood pressure changes in any of the studies met the age and sex-dependent criteria for hypertension. Evidence supporting increases in blood pressure with pubertal suppression is largely limited to uncontrolled retrospective studies (Klaver et al. 2020; Perl et al. 2020) with prospective studies being conducted (Millington et al. 2020).

Improving height potential

Long-acting GnRH agonists are used to preserve height potential in children with rapidly progressive forms of central precocious puberty (CPP) (Eugster 2019). An observation period of 6 months may be necessary in female adolescents prior to Tanner stage B2 to exclude forms of CPP which do not respond to treatment (Carel, et al. 2009). Female adolescents under the age of 8 derive the most benefit from treatment (Bertelloni, et al. 2017). In addition, GnRH agonists may be used alongside growth hormone (GH) to improve height in children with idiopathic short stature (Cohen, et al. 2008), GH deficiency (GH Research Society 2000) or those born with small for gestational age (Lem, et al. 2012).

The infrequent use of GnRH agonists to improve height potential may explain the paucity of evidence surrounding their cardiovascular effects. To date, only three cases of hypertension have been reported in children treated for CPP (Calcaterra, et al. 2013; Palma, et al. 2018; Siomou, et al. 2014).

Discussion

We have described the clinical uses of GnRH analogues (Fig. 1) and their reported cardiovascular effects (Table 3). Data from observational studies suggest that GnRH agonists increase the risk of ischaemic heart disease (Liang et al. 2020) and stroke (Liu et al. 2020) among adult males. No changes in blood pressure were recorded (Dockery et al. 2003; Smith et al. 2008). Comparisons between GnRH antagonists and agonists remain inconclusive.

In females treated with breast cancer, clinical trials have established the link between GnRH agonists and the development of hypertension (Francis et al. 2018; Regan et al. 2013), an effect that remains uncertain among females treated with uterine fibroids (Schlaff et al. 2020) or endometriosis (Ferreira et al. 2010). Similar associations have been observed between GnRH analogue-based IVF therapy with pre-eclampsia (Calhoun et al. 2011; Jackson et al. 2004) and gestational hypertension (Shevell et al. 2005) but not stroke (Dayan et al. 2017). Conversely, females with breast cancer receiving GnRH agonists are shown to have a lower risk of developing ischaemic heart disease (Chou et al. 2022).

The transgender population faces lifelong disparities in healthcare, largely driven by biological and psychosocial factors (Streed, et al. 2021). These disparities manifest as a higher incidence of myocardial infarction among transgender populations (Alzahrani, et al. 2019). Whether this reflects differences in clinical risk factors remains uncertain, and may be a consequence of behavioural risk factors, such as smoking (Kcomt, et al. 2020) and lack of physical activity (Gilani, et al. 2021). However, the long-term cardiovascular effects of puberty blockers in transgender adolescents remain uncertain.

Patients receiving GnRH analogues have a higher baseline cardiovascular risk, which may be confounded by comorbidities, including malignancy and infertility (Fig. 3). In view of this, observational studies involving males with prostate cancer (Keating et al. 2006; Keating et al. 2010; Van Hemelrijck et al. 2010) and infertility (Calhoun et al. 2011; Jackson

et al. 2004; Shevell et al. 2005) have adjusted for baseline demographics and comorbidities. However, these analyses may have left out confounders that were not identified or recorded. Conversely, the increase in cardiovascular events may reflect improved overall survival among cancer patients treated with endocrine therapy (Francis et al. 2018). In addition, several cancer therapies lead to direct and indirect cardiovascular toxicity (Crocetto, et al. 2023), highlighting the need to evaluate the cardiovascular safety of such treatment.

Furthermore, the metabolic effects of GnRH agonists are well established. GnRH agonists led to a shift in body composition from lean mass to fat mass (Mueller, et al. 2011; Smith, et al. 2006; Smith et al. 2008), hyperinsulinaemia (Dockery et al. 2003), reduced insulin sensitivity (Smith et al. 2006) and diabetes mellitus (Keating et al. 2010). In contrast to GnRH agonists, oral antiandrogens were not associated with an increased risk of diabetes amongst males with prostate cancer (Keating et al. 2010), suggesting a role of GnRH signal disruption in the development of diabetes.

In male mice models, GnRH agonists led to the destabilisation of established atherosclerotic plaques, a process likely caused by T cell-mediated inflammation (Knutsson et al. 2016). The activation of GnRH receptors present on T-cells (Chen, et al. 1999) may stimulate their pro-inflammatory activity (Tanriverdi, et al. 2005). The lack of such a response in mice treated with GnRH antagonists suggests that the cardiovascular effects of GnRH agonist are largely driven by the initial surge of gonadotropins and testosterone (Knutsson et al. 2016). While GnRH and FSH receptors are known to be expressed within the vasculature (Chegini, et al. 1996; Stillely and Segaloff 2018), their function and effects on cardiovascular disease remain unknown.

In conclusion, although GnRH analogues share a common mechanism, their wide application and interaction with sex alters cardiovascular risk via multitude of mechanisms. Uncertainty remains whether the effects are due to gonadotropin antagonism, a consequence of hypogonadism, or a combination of both factors. Clinical context with respect to cardiovascular risk should be considered to provide disease monitoring and

initiate early intervention (Levine et al. 2010). Raised baseline cardiovascular risk should be a consideration but not an absolute contraindication. Further research is required to understand the role of GnRH and its downstream effectors in cardiovascular health and disease.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work was supported by the British Heart Foundation (grant number RE/18/6/34217) and the NES/CSO Clinical Lectureship (grant number PCL/21/05).

References

Akçay M & Özdemir AZ 2021 Effect of supraphysiological estrogen levels on arterial stiffness and hemodynamic parameters. *Anatolian Journal of Cardiology* **25** 346-351.

Albano C, Smitz J, Camus M, Riethmüller-Winzen H, Siebert-Weigel M, Diedrich K, Van Steirteghem AC & Devroey P 1996 Hormonal profile during the follicular phase in cycles stimulated with a combination of human menopausal gonadotrophin and gonadotrophin-releasing hormone antagonist (Cetrorelix). *Human Reproduction* **11** 2114-2118.

Alzahrani T, Nguyen T, Ryan A, Dwairy A, McCaffrey J, Yunus R, Forgione J, Krepp J, Nagy C, Mazhari R & Reiner J 2019 Cardiovascular Disease Risk Factors and Myocardial Infarction in the Transgender Population. *Circulation: Cardiovascular Quality and Outcomes* **12** e005597.

Banks K, Kyinn M, Leemaqz SY, Sarkodie E, Goldstein D & Irwig MS 2021 Blood Pressure Effects of Gender-Affirming Hormone Therapy in Transgender and Gender-Diverse Adults. *Hypertension* **77** 2066-2074.

Bertelloni S, Massart F, Miccoli M & Baroncelli GI 2017 Adult height after spontaneous pubertal growth or GnRH analog treatment in girls with early puberty: a meta-analysis. *European Journal of Pediatrics* **176** 697-704.

Brown J, Pan A & Hart RJ 2010 Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. *Cochrane Database of Systematic Reviews*.

Bui KT, Willson ML, Goel S, Beith J & Goodwin A 2020 Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer. *Cochrane Database of Systematic Reviews* **3** CD013538.

Bulun SE 2009 Endometriosis. *New England Journal of Medicine* **360** 268-279.

Burstein HJ 2020 Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer. *New England Journal of Medicine* **383** 2557-2570.

Calcaterra V, Mannarino S, Corana G, Codazzi AC, Mazzola A, Brambilla P & Larizza D 2013 Hypertension during therapy with triptorelin in a girl with precocious puberty. *Indian Journal of Pediatrics* **80** 884-885.

Calhoun KC, Barnhart KT, Elovitz MA & Srinivas SK 2011 Evaluating the Association between Assisted Conception and the Severity of Preeclampsia. *ISRN Obstetrics and Gynecology* **2011** 928592.

Cardwell CR, O'Sullivan JM, Jain S, Harbinson MT, Cook MB, Hicks BM & McMenamin ÚC 2020 The Risk of Cardiovascular Disease in Prostate Cancer Patients Receiving Androgen Deprivation Therapies. *Epidemiology* **31** 432-440.

Carel J-C, Eugster EA, Rogol A, Ghizzoni L & Palmert MR 2009 Consensus Statement on the Use of Gonadotropin-Releasing Hormone Analogs in Children. *Pediatrics* **123** e752-e762.

Chegini N, Rong H, Dou Q, Kipersztok S & Williams RS 1996 Gonadotropin-releasing hormone (GnRH) and GnRH receptor gene expression in human myometrium and leiomyomata and the direct action of GnRH analogs on myometrial smooth muscle cells and interaction with ovarian steroids in vitro. *Journal of Clinical Endocrinology and Metabolism* **81** 3215-3221.

Chen D-Y, Su P-J, See L-C, Liu J-R, Chuang C-K, Pang S-T, Tseng C-N, Chen S-W, Hsieh IC, Chu P-H, et al. 2021 Gonadotropin-releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin-releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro study. *The Prostate* **81** 902-912.

Chen D, Berona J, Chan Y-M, Ehrensaft D, Garofalo R, Hidalgo MA, Rosenthal SM, Tishelman AC & Olson-Kennedy J 2023 Psychosocial Functioning in Transgender Youth after 2 Years of Hormones. *New England Journal of Medicine* **388** 240-250.

Chen H-F, Jeung E-B, Stephenson M & Leung PCK 1999 Human Peripheral Blood Mononuclear Cells Express Gonadotropin-Releasing Hormone (GnRH), GnRH Receptor, and Interleukin-2 Receptor γ -Chain Messenger Ribonucleic Acids That Are Regulated by GnRH in Vitro¹. *The Journal of Clinical Endocrinology & Metabolism* **84** 743-750.

Chou YS, Wang CC, Hsu LF, Chuang PH, Cheng CF, Li NH, Chen CC, Chen CL, Lai YJ & Yen YF 2022 Gonadotropin-releasing hormone agonist treatment and ischemic heart disease among female patients with breast cancer: A cohort study. *Cancer Medicine*.

Cirne F, Aghel N, Petropoulos J-A, Klotz L, Lenihan DJ, Saad F, Pinthus J & Leong DP 2021 The Cardiovascular Effects of GnRH Antagonists in Men with Prostate Cancer. *European Heart Journal - Cardiovascular Pharmacotherapy*.

Claahsen - van der Grinten H, Verhaak C, Steensma T, Middelberg T, Roeffen J & Klink D 2021 Gender incongruence and gender dysphoria in childhood and adolescence—current insights in diagnostics, management, and follow-up. *European Journal of Pediatrics* **180** 1349-1357.

Cohen P, Rogol AD, Deal CL, Saenger P, Reiter EO, Ross JL, Chernausek SD, Savage MO & Wit JM 2008 Consensus Statement on the Diagnosis and Treatment of Children with Idiopathic Short Stature: A Summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. *The Journal of Clinical Endocrinology & Metabolism* **93** 4210-4217.

Connelly PJ, Marie Freel E, Perry C, Ewan J, Touyz RM, Currie G & Delles C 2019 Gender-Affirming Hormone Therapy, Vascular Health and Cardiovascular Disease in Transgender Adults. *Hypertension* **74** 1266-1274.

Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, et al. 2021 EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. *European Urology* **79** 263-282.

Crocetto F, Ferro M, Buonerba C, Bardi L, Dolce P, Scafuri L, Mirto BF, Verde A, Sciarra A, Barone B, et al. 2023 Comparing cardiovascular adverse events in cancer patients: A meta-

analysis of combination therapy with angiogenesis inhibitors and immune checkpoint inhibitors versus angiogenesis inhibitors alone. *Critical Reviews in Oncology/Hematology* **188** 104059.

Davey P & Kirby MG 2021 Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice. *World Journal of Urology* **39** 307-315.

Davidson NE, O'Neill AM, Vukov AM, Osborne CK, Martino S, White DR & Abeloff MD 2005 Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). *Journal of Clinical Oncology* **23** 5973-5982.

Dayan N, Filion KB, Okano M, Kilmartin C, Reinblatt S, Landry T, Basso O & Udell JA 2017 Cardiovascular Risk Following Fertility Therapy: Systematic Review and Meta-Analysis. *Journal of the American College of Cardiology* **70** 1203-1213.

Delemarre-Van De Waal HA & Cohen-Kettenis PT 2006 Clinical management of gender identity disorder in adolescents: A protocol on psychological and paediatric endocrinology aspects. *European Journal of Endocrinology, Supplement* **155** S131-S137.

Dockery F, Bulpitt CJ, Agarwal S, Donaldson M & Rajkumar C 2003 Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. *Clinical Science (London, England: 1979)* **104** 195-201.

Eugster EA 2019 Treatment of Central Precocious Puberty. *Journal of the Endocrine Society* **3** 965-972.

Farland LV, Grodstein F, Srouji SS, Forman JP, Rich-Edwards J, Chavarro JE & Missmer SA 2015 Infertility, fertility treatment, and risk of hypertension. *Fertility and Sterility* **104** 391-397.

Ferreira RA, Vieira C, Rosa-E-Silva J, Rosa-e-Silva A, Nogueira A & Ferriani R 2010 Effects of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers in patients with endometriosis: a comparative study with the GnRH analogue. *Contraception*.

Flanagan CA & Manilall A 2017 Gonadotropin-Releasing Hormone (GnRH) Receptor Structure and GnRH Binding. *Frontiers in Endocrinology* **8** 274.

Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, Gómez HL, Tondini C, Ciruelos E, Burstein HJ, et al. 2018 Tailoring adjuvant endocrine therapy for premenopausal breast cancer. *New England Journal of Medicine* **379** 122-137.

George G, Garmo H, Scailteux L-M, Balusson F, Coster GD, Schutter HD, Kuiper JG, Oger E, Verbeeck J & Hemelrijck MV 2021 Risk of cardiovascular disease following gonadotropin-releasing hormone agonists vs antagonists in prostate cancer: Real-world evidence from five databases. *International Journal of Cancer* **148** 2203-2211.

GH Research Society 2000 Consensus Guidelines for the Diagnosis and Treatment of Growth Hormone (GH) Deficiency in Childhood and Adolescence: Summary Statement of the GH Research Society¹. *The Journal of Clinical Endocrinology & Metabolism* **85** 3990-3993.

Gilani M, Wallach P & Kyriakou A 2021 Levels of physical activity and barriers to sport participation in young people with gender dysphoria. *Journal of Pediatric Endocrinology and Metabolism* **34** 747-753.

Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V & T'Sjoen GG 2017 Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. *The Journal of Clinical Endocrinology and Metabolism* **102** 3869-3903.

Hopmans SN, Duivenvoorden WC, Werstuck GH, Klotz L & Pinthus JH 2014 GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model. *Urologic Oncology* **32** 1126-1134.

Huang B, Warner M & Gustafsson J-Å 2015 Estrogen receptors in breast carcinogenesis and endocrine therapy. *Molecular and Cellular Endocrinology* **418** 240-244.

Hupe MC, Hammerer P, Ketz M, Kossack N, Colling C & Merseburger AS 2018 Retrospective Analysis of Patients With Prostate Cancer Initiating GnRH Agonists/Antagonists Therapy Using a German Claims Database: Epidemiological and Patient Outcomes. *Frontiers in Oncology* **8** 543.

Irgens HU, Reisaeter L, Irgens LM & Lie RT 2001 Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. *BMJ* **323** 1213-1217.

Jackson RA, Gibson KA, Wu YW & Croughan MS 2004 Perinatal outcomes in singletons following in vitro fertilization: a meta-analysis. *Obstetrics and Gynecology* **103** 551-563.

Janssen EB, Rijkers ACM, Hoppenbrouwers K, Meuleman C & D'Hooghe TM 2013 Prevalence of endometriosis diagnosed by laparoscopy in adolescents with dysmenorrhea or chronic pelvic pain: a systematic review. *Human Reproduction Update* **19** 570-582.

Kcomt L, Evans-Polce RJ, Veliz PT, Boyd CJ & McCabe SE 2020 Use of Cigarettes and E-Cigarettes/Vaping Among Transgender People: Results From the 2015 U.S. Transgender Survey. *American Journal of Preventive Medicine* **59** 538-547.

Keating NL, O'Malley AJ & Smith MR 2006 Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. *Journal of Clinical Oncology* **24** 4448-4456.

Keating NL, O'Malley AJ, Freedland SJ & Smith MR 2010 Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate Cancer. *JNCI: Journal of the National Cancer Institute* **102** 39-46.

Klaver M, de Mutsert R, van der Loos MATC, Wiepjes CM, Twisk JWR, den Heijer M, Rotteveel J & Klink DT 2020 Hormonal Treatment and Cardiovascular Risk Profile in Transgender Adolescents. *Pediatrics* **145**.

Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK & Schroder FH 2008 The efficacy and safety of degarelix: a 12-month, comparative,

randomized, open-label, parallel-group phase III study in patients with prostate cancer. *BJU International* **102** 1531-1538.

Knutsson A, Hsiung S, Celik S, Rattik S, Mattisson IY, Wigren M, Scher HI, Nilsson J & Hultgårdh-Nilsson A 2016 Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE(-/-) mice. *Scientific Reports* **6** 26220.

Lem AJ, van der Kaay DCM, de Ridder MAJ, Bakker-van Waarde WM, van der Hulst FJPCM, Mulder JC, Noordam C, Odink RJ, Oostdijk W, Schroor EJ, et al. 2012 Adult Height in Short Children Born SGA Treated with Growth Hormone and Gonadotropin Releasing Hormone Analog: Results of a Randomized, Dose-Response GH Trial. *The Journal of Clinical Endocrinology & Metabolism* **97** 4096-4105.

Lethaby A, Puscasiu L & Vollenhoven B 2017 Preoperative medical therapy before surgery for uterine fibroids. *Cochrane Database of Systematic Reviews* **11** CD000547.

Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR & Zakai N 2010 Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk. *Circulation* **121** 833-840.

Li Y, Sun X, Zang L, Zhang Q, Li J & Zou S 2013 Correlation between steroid hormonal levels and cardiac function in women during controlled ovarian hyperstimulation. *Endocrine* **44** 784-789.

Liang Z, Zhu J, Chen L, Xu Y, Yang Y, Hu R, Zhang W, Song Y, Lu Y, Ou N & Liu X 2020 Is androgen deprivation therapy for prostate cancer associated with cardiovascular disease? A meta-analysis and systematic review. *Andrology* **8** 559-574.

Linden Mvd, Buckingham K, Farquhar C, Kremer JAM & Metwally M 2015 Luteal phase support for assisted reproduction cycles. *Cochrane Database of Systematic Reviews*.

Liu R, Zhou J, Xia S & Li T 2020 Androgen deprivation therapy and the risk of stroke in patients with prostate cancer: an updated systematic review and meta-analysis. *Urologia Internationalis* **104** 214-221.

Lopes RD, Higano CS, Slovin SF, Nelson AJ, Bigelow R, Sørensen PS, Melloni C, Goodman SG, Evans CP, Nilsson J, et al. 2021 Cardiovascular Safety of Degarelix versus Leuprolide in Patients with Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. *Circulation* **0**.

Manau D, Arroyo V, Jiménez W, Fábregues F, Vanrell JA & Balasch J 2002 Chronology of hemodynamic changes in asymptomatic in vitro fertilization patients and relationship with ovarian steroids and cytokines. *Fertility and Sterility* **77** 1178-1183.

Millington K, Schulmeister C, Finlayson C, Grabert R, Olson-Kennedy J, Garofalo R, Rosenthal SM & Chan Y-M 2020 Physiological and Metabolic Characteristics of a Cohort of Transgender and Gender-Diverse Youth in the United States. *Journal of Adolescent Health* **67** 376-383.

Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, et al. 2021 EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. *European Urology* **79** 243-262.

Mueller A, Zollver H, Kronawitter D, Oppelt PG, Claassen T, Hoffmann I, Beckmann MW & Dittrich R 2011 Body composition and bone mineral density in male-to-female transsexuals during cross-sex hormone therapy using gonadotrophin-releasing hormone agonist. *Experimental and Clinical Endocrinology & Diabetes* **119** 95-100.

Packer JR & Maitland NJ 2016 The molecular and cellular origin of human prostate cancer. *Biochimica et Biophysica Acta* **1863** 1238-1260.

Palma L, Gaudino R, Cavarzere P & Antoniazzi F 2018 Does the risk of arterial hypertension increase in the course of triptorelin treatment? *Journal of Pediatric Endocrinology and Metabolism* **33** 449-452.

Perl L, Segev-Becker A, Israeli G, Elkon-Tamir E & Oren A 2020 Blood pressure dynamics after pubertal suppression with gonadotropin-releasing hormone analogs followed by testosterone treatment in transgender male adolescents: a pilot study. *LGBT Health* **7** 340-344.

Perl L, Elkon-Tamir E, Segev-Becker A, Israeli G, Brener A & Oren A 2021 Blood pressure dynamics after pubertal suppression with gonadotropin-releasing hormone analogs followed by estradiol treatment in transgender female adolescents: a pilot study. *Journal of Pediatric Endocrinology and Metabolism* **34** 741-745.

Persson B-E, Olesen TK & Jensen J-K 2009 Degarelix: A New Approach for the Treatment of Prostate Cancer. *Neuroendocrinology* **90** 235-244.

Regan MM, Pagani O, Fleming GF, Walley BA, Price KN, Rabaglio M, Maibach R, Ruepp B, Coates AS, Goldhirsch A, et al. 2013 Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trials. *The Breast* **22** 1094-1100.

Scailteux L-M, Vincendeau S, Balusson F, Leclercq C, Happe A, Le Nautout B, Polard E, Nowak E & Oger E 2017 Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists—a nationwide population-based cohort study based on 2010–2013 French Health Insurance data. *European Journal of Cancer* **77** 99-108.

Schlaff WD, Ackerman RT, Al-Hendy A, Archer DF, Barnhart KT, Bradley LD, Carr BR, Feinberg EC, Hurtado SM, Kim J, et al. 2020 Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids. *New England Journal of Medicine* **382** 328-340.

Sciarra A, Busetto GM, Salciccia S, Del Giudice F, Maggi M, Crocetto F, Ferro M, De Berardinis E, Scarpa RM, Porpiglia F, et al. 2021 Does Exist a Differential Impact of Degarelix Versus LHRH Agonists on Cardiovascular Safety? Evidences From Randomized and Real-World Studies. *Frontiers in Endocrinology* **12** 687.

Shahinian VB, Kuo YF, Freeman JL & Goodwin JS 2005 Risk of fracture after androgen deprivation for prostate cancer. *New England Journal of Medicine* **352** 154-164.

Shevell T, Malone FD, Vidaver J, Porter TF, Luthy DA, Comstock CH, Hankins GD, Eddleman K, Dolan S, Dugoff L, et al. 2005 Assisted reproductive technology and pregnancy outcome. *Obstetrics and Gynecology* **106** 1039-1045.

Shore ND 2013 Experience with degarelix in the treatment of prostate cancer. *Therapeutic Advances in Urology* **5** 11-24.

Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, Akaza H, Bossi A, van Veenhuizen DF, Selby B, et al. 2020 Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. *New England Journal of Medicine* **382** 2187-2196.

Siomou E, Kosmeri C, Pavlou M, Vlahos AP, Argyropoulou MI & Siamopoulou A 2014 Arterial hypertension during treatment with triptorelin in a child with Williams–Beuren syndrome. *Pediatric Nephrology* **29** 1633-1636.

Smith MR, Lee H & Nathan DM 2006 Insulin sensitivity during combined androgen blockade for prostate cancer. *Journal of Clinical Endocrinology and Metabolism* **91** 1305-1308.

Smith MR, Klotz L, Persson BE, Olesen TK & Wilde AA 2010 Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. *Journal of Urology* **184** 2313-2319.

Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL & Finkelstein JS 2008 Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. *Cancer* **112** 2188-2194.

Stilley JAW & Segaloff DL 2018 FSH Actions and Pregnancy: Looking Beyond Ovarian FSH Receptors. *Endocrinology* **159** 4033-4042.

Stoffers IE, de Vries MC & Hannema SE 2019 Physical changes, laboratory parameters, and bone mineral density during testosterone treatment in adolescents with gender dysphoria. *Journal of Sexual Medicine* **16** 1459-1468.

Streed CG, Beach LB, Caceres BA, Dowshen NL, Moreau KL, Mukherjee M, Poteat T, Radix A, Reisner SL, Singh V & null n 2021 Assessing and Addressing Cardiovascular Health in People Who Are Transgender and Gender Diverse: A Scientific Statement From the American Heart Association. *Circulation* **144** e136-e148.

Sturgeon KM, Deng L, Bluethmann SM, Zhou S, Trifiletti DM, Jiang C, Kelly SP & Zaorsky NG 2019 A population-based study of cardiovascular disease mortality risk in US cancer patients. *European Heart Journal* **40** 3889-3897.

Sun Y, Xie L, Xu T, Jakobsen JS, Han W, Sørensen PS & Wang X 2020 Efficacy and safety of degarelix in patients with prostate cancer: Results from a phase III study in China. *Asian Journal of Urology* **7** 301-308.

Tanriverdi F, Gonzalez-Martinez D, Hu Y, Kelestimur F & Bouloux PMG 2005 GnRH-I and GnRH-II have differential modulatory effects on human peripheral blood mononuclear cell proliferation and interleukin-2 receptor γ -chain mRNA expression in healthy males. *Clinical and Experimental Immunology* **142** 103-110.

Udell JA, Lu H & Redelmeier DA 2013 Long-Term Cardiovascular Risk in Women Prescribed Fertility Therapy. *Journal of the American College of Cardiology* **62** 1704-1712.

Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, Bill-Axelsson A, Lambe M, Stattin P & Adolfsson J 2010 Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the population-based pcbase sweden. *Journal of Clinical Oncology* **28** 3448-3456.

Wegienka G, Baird DD, Hertz-Picciotto I, Harlow SD, Steege JF, Hill MC, Schectman JM & Hartmann KE 2003 Self-reported heavy bleeding associated with uterine leiomyomata. *Obstetrics and Gynecology* **101** 431-437.

Westerlund E, Brandt L, Hovatta O, Wallén H, Ekblom A & Henriksson P 2014 Incidence of hypertension, stroke, coronary heart disease, and diabetes in women who have delivered after in vitro fertilization: a population-based cohort study from Sweden. *Fertility and Sterility* **102** 1096-1102.

Williams MR, Walker KJ, Turkes A, Blamey RW & Nicholson RI 1986 The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. *British Journal of Cancer* **53** 629-636.

Youssef MAFM, Veen FVd, Al-Inany HG, Mochtar MH, Griesinger G, Mohesen MN, Aboulfoutouh I & Wely Mv 2014 Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. *Cochrane Database of Systematic Reviews*.


Zhao J, Zhu S, Sun L, Meng F, Zhao L, Zhao Y, Tian H, Li P & Niu Y 2014 Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. *PloS One* **9** e107516.


1 **Figure legends**

2 **Fig. 1 | Indications of GnRH analogues.** In adults, the GnRH receptor is utilised as a target
3 in the management of malignancies (prostate and breast cancer), benign growths (uterine
4 fibroids and endometriosis), infertility and masculinising and feminising treatment. In
5 children, GnRH analogues are used to suppress puberty for gender dysphoria and to
6 preserve height potential for central precocious puberty, idiopathic short stature, growth
7 hormone (GH) deficiency or small for gestational age (SGA).

8 **Fig. 2 | Effects of GnRH analogues on the hypothalamic-pituitary-gonadal axis.** GnRH
9 is secreted from hypothalamic neurones and regulates the synthesis of gonadotropins FSH
10 and LH via the anterior pituitary receptors. Gonadotropins, in turn, modulate a multitude of
11 reproductive processes through the action of the gonadal sex steroids and maintenance of
12 negative feedback along this axis. Agonistic GnRH stimulation (-relin) promotes
13 gonadotropin and sex hormone secretion; however, chronic stimulation results in GnRH
14 receptor downregulation and relative hypogonadism. GnRH antagonists (-lix) directly inhibit
15 these receptors thereby suppressing gonadotropin and sex steroid secretion.

16 **Fig. 3 | Possible explanations for sex differences in cardiovascular effects.** GnRH
17 analogues may contribute to cardiovascular disease via three main processes -
18 atherosclerosis, hypertension and adverse metabolic changes. Infertility and cancer are
19 major confounding factors among users of GnRH analogues








Table 1 | Comparative effects of GnRH analogues in clinical trials.

Study	Population	Drugs	Mean duration	Outcome HR (95% CI)
(Lopes et al. 2021) "PRONOUNCE"	276 antagonist and 269 agonist	Degarelix vs Leuprorelin	12 m	MACE 1.28 (0.59, 2.79)
(Smith et al. 2010)	416 antagonist and 204 agonist	Degarelix vs Leuprorelin	12 m	IHD 0.88, p>0.05
(Sun et al. 2020)	142 antagonist and 141 agonist	Degarelix vs Goserelin	12 m	MACE 0.73 (0.35, 1.53)
(Shore et al. 2020) "HERO"	622 antagonist and 308 agonist	Relugolix vs Leuprorelin	48 w	MACE 0.46 (0.24, 0.88) CV mortality 0.39 (0.14, 1.02)

Abbreviations: HR - hazard ratio; MACE - major adverse cardiovascular events; IHD - ischaemic heart disease; CV - cardiovascular

Table 2 | Blood pressure changes in transgender adolescents receiving GnRH agonist triptorelin for pubertal suppression.

First Author	Population	Study Design	Mean duration \pm SD	Changes in blood pressure (95% CI)
(Perl et al. 2021)	19 TGF	Retrospective	9 \pm 6 m	SBP + 0 mmHg, ns DBP + 0 mmHg, ns
(Klaver et al. 2020)	71 TGF	Retrospective	2.1 (1.0 - 2.7) m*	SBP + 1 mmHg (- 3, 5), ns DBP + 4 mmHg (1, 7), p<0.005
	121 TGM	Retrospective	1.0 (0.5 - 2.9) m*	SBP + 2 mmHg (- 1, 4), ns DBP + 1 mmHg (- 1, 3), ns
(Perl et al. 2020)	15 TGM	Retrospective	3 \pm 1 m	SBP + 1 mmHg, ns DBP + 7 mmHg, p=0.009
(Stoffers et al. 2019)	62 TGM	Prospective	8 (3 - 39) m*	SBP - 6 mmHg, ns DBP + 4 mmHg, ns

Abbreviations: SD - standard deviation; CI - confidence interval; TGF - transfeminine adolescent (natal male); TGM - transmasculine adolescent (natal female); SBP - systolic blood pressure; DBP - diastolic blood pressure; ns - not significant. *Presented as median (interquartile range)

Table 3 | Effects of GnRH agonists on cardiovascular disease.

Condition	Male	Female	Strength of Evidence*
Ischaemic heart disease	↑	↓	B - C
Stroke / TIA	↑	↔	B - B
Hypertension	↔	↑	C - A

Abbreviations: TIA - transient ischaemic attack; ↑ indicates an increase in risk; ↓ indicates a decrease in risk; ↔ indicates no difference in risk.

*A: evidence derived from more than 1 randomised controlled trials; B: evidence derived from a single randomised controlled trial or more than 1 observational studies; C: evidence derived from a single observational study.

Supplementary Table 1 | Evidence Behind the FDA Decision.

First Author	Population	Median follow-up	Treatment	Outcome	HR (95% CI)
(Keating et al. 2006)	73196 males with locoregional prostate cancer	4.6 y	Goserelin or leuprorelin vs no ADT	IHD	1.16 (1.10, 1.21)
				MI	1.11 (1.01, 1.21)
				SCD	1.16 (1.05, 1.27)
(Keating et al. 2010)	37443 males with locoregional prostate cancer	2.6 y	Goserelin or leuprorelin vs no ADT	IHD	1.19 (1.10, 1.28)
				MI	1.28 (1.08, 1.52)
				SCD	1.35 (1.18, 1.54)
				Stroke	1.22 (1.10, 1.36)
(Van Hemelrijck et al. 2010)	76600 males with prostate cancer	3.8 y*	GnRH agonist†	IHD	1.30 (1.17, 1.45)
				MI	1.28 (1.11, 1.47)
				Stroke	1.27 (1.12, 1.43)
				Heart failure	1.46 (1.28, 1.67)
				Arrhythmia	1.27 (1.10, 1.47)

Abbreviations: HR - hazard ratio; CI - confidence interval; ADT - androgen deprivation therapy; IHD - ischaemic heart disease; MI - myocardial infarction; SCD - sudden cardiac death. *Mean follow-up; †GnRH agonist users were compared to the general population